vestronidase alfa-vjbk


ves-tron-i-dase al-fa vjbk

Trade Name(s)

  • Mepsevii

Ther. Class.
replacement enzyme

Pharm. Class.


Mucopolysaccharidosis (MPS) VII.


Recombinant form of human beta-glucuronidase (GUS) which is taken up by lysosomes and causing catabolism of accumulated (GAGs) in affected tissues.

Therapeutic Effect(s):

Improved motor and pulmonary function and reduced liver and spleen volumes.


Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism and Excretion: Eliminated by proteolytic degradation into small peptides and amino acids.

Half-life: 2.6 hr

TIME/ACTION PROFILE (serum concentrations)



Contraindicated in:

  • None.

Use Cautiously in:

OB:  Lactation: Safety not established

Adverse Reactions/Side Effects

CV: peripheral edema

Derm: pruritus, rash

GI: diarrhea

Misc: ANAPHYLAXIS, extravasation, infusion site reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



None known.


IV (Adults and Children): 4 mg/kg every 2 wk.


Solution for IV infusion (must be diluted): 2 mg/mL


  • Assess for signs and symptoms of infusion reaction (respiratory distress, cyanosis, decreased oxygen saturation, hypotension) during and for at least 60 min after completion of infusion. Discontinue infusion immediately if signs and symptoms of anaphylaxis occur.
  • Obtain patient weigh prior to infusion to determine dose.

Potential Diagnoses


IV Administration

  • Administer a non-sedating antihistamine 30–60 min prior to start of infusion.
  • Intermittent Infusion:  Allow vials to reach room temperature before diluting; do not heat, microwave, or shake. Solution is clear and colorless to slightly yellow; may have thin translucent fibers. Do not administer solutions that are discolored or contain particulate matter. Use an 18 gauge needle to slowly remove dose from vials to avoid agitation, turbulence, or bubbles. Slowly add solution to empty infusion bag. Add 0.9% NaCl equal to volume of medication. Gently rock bag to mix; do not shake.
  • Rate: Infuse via in-line, low-protein binding 0.2 micron filter over 4 hr. Infuse first 2.5% of total volume over first hr. Account for dead space in lines to ensure 2.5% of total infusion volume is delivered into patient's bloodstream during 1st hr of infusion. Then increase infusion rate as tolerated to complete infusion over following 3 hrs. Do not flush line to prevent rapid bolus of medication. May add 0.9% NaCl through y-site or piggyback to maintain flow and prevent clotting or line blockage. Complete infusion within 42 hr of dilution. Solution is stable for 6 hr at room temperature or 36 hr if refrigerated.
  • Y-Site Incompatibility: Do not administer other products through infusion tubing.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Instruct patient to notify health care professional immediately if signs and symptoms of anaphylaxis (rash, pruritus, hives, swelling of face and neck, dyspnea, fainting, dizziness, feeling lightheaded) occur.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Improved motor and pulmonary function and reduced liver and spleen volumes.

vestronidase alfa-vjbk is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. .